| Buffett Is Sitting on $344B and Here’s Why It Matters Now |
The obesity issue is bursting at the seams.
According to the World Health Organization, obesity has more than doubled since 1990. Adolescent obesity has quadrupled. About 390 million children and adolescents aged five to 19 years were overweight in 2022, including 160 million who were living with obesity.
Fortunately, we’re seeing big advancements in medications being used to combat the issue.
Look at Novo Nordisk (NVO)
Novo Nordisk’s Wegovy just won approval of its GLP-1 pill and expects to launch the pill in early January. The company also expects the pill to help people lose as much weight as with the injections.
“In the 64-week OASIS 4 study of 307 adults without diabetes, participants taking the pill alongside lifestyle changes lost an average of 16.6% of body weight, compared with 2.7% for placebo. Over a third (34.4%) achieved at least 20% weight loss, versus 2.9% for placebo,” said the company in a recent press release.
This should be big news for the beaten down NVO stock.
Since peaking at $62.50 in September, NVO now trades at $48.10. From here, given the potential for further weight loss success, we’d like to see it rally to $55 initially.
Viking Therapeutics (VKTX)
Obesity treatment company, Viking Therapeutics is also seeing upside thanks to Novo Nordisk.
Most recently, VKTX completed “enrolling study participants in the phase III VANQUISH-1 study, which is evaluating the safety and efficacy of the subcutaneous (SC) formulation of its investigational obesity drug, VK2735,” as noted in a Viking press release.
“Earlier this year, the company completed enrollment in the phase II VENTURE-Oral Dosing study that evaluated the oral formulation of VK2735. This study, which was announced in January, reached full enrollment by March.”
As we wait for results, analysts at HC Wainright has a buy rating on the VKTX stock with a price target of $102.
Fueling more upside for obesity stocks, the global obesity treatment market could grow to $130 billion by 2030, according to Goldman Sachs.
Even Morgan Stanley expects the global obesity drug treatment market to reach $105 billion by 2030 from $77 billion. At the high end, $144 billion.
Up Next: Elon’s “XG” Coming for $2 TRILLION Market?
Now that SpaceX has announced its plans to go public…
Everyone is wondering “what’s Elon’s next move?”
And according to my research, it could be what I call “Project XG”…
A plan to utilize Starlink’s global satellite network to beam ultra-fast Internet to all 5.7 BILLION cell phones on earth…
And could be worth over $2 TRILLION when all is said and done.
“Project XG” could be the most transformative cellular technology we’ve ever seen…
Connecting every phone on earth to the fastest wireless network ever conceived…
And it’s one BIG reason why I believe SpaceX’s IPO is now projected to hit a staggering $1.5 TRILLION valuation.
For reference, the biggest IPO to date was Saudi Aramco… at a mere $25.6 billion.
That means…
SpaceX’s IPO could be 58X BIGGER than the largest IPO in history.
When this happens, I believe “Project XG” won’t be far behind.
But here’s the thing…
You do NOT have to be left out of this once-in-a-lifetime opportunity.
In fact, you can get action on this SpaceX IPO right now – before it goes public …
And you can get in, using a regular brokerage account, for less than $100.
Click here for the full story.
It sounds nuts…
But this is your chance to beat Wall Street to the punch…
And get a piece of the action on the BIGGEST IPO in history…
Before the news even hits the market.
Do NOT miss this opportunity.
Found this helpful? Share it with others.
Written by Ian Cooper